Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.57 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.51 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.50 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.50 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.50 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.49 |
| ▸ | NAAA | Q02083 | 1/20 | 0.49 |
| ▸ | PRKCA | P17252 | 4/20 | 0.48 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | PAM | P19021 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14940755 | 1.00 | DGKA (0.57) | DGKAALOX5EPHX2PRSS1PRSS2 | |
| SCHEMBL14944798 | 0.93 | DGKA (0.53) | DGKAALOX5EPHX2PRSS1PRSS2 | |
| SCHEMBL10081238 | 0.93 | DGKA (0.54) | DGKAALOX5EPHX2PRSS1PRSS2 | |
| SCHEMBL14944813 | 0.92 | MGLL (0.50) | DGKAALOX5EPHX2PRKCAPRKCE | |
| SCHEMBL14940598 | 0.90 | ALOX5 (0.55) | DGKAALOX5EPHX2DNM1NAAA | |
| SCHEMBL12794339 | 0.90 | DNM1 (0.59) | DGKAALOX5EPHX2PRSS1PRSS2 | |
| SCHEMBL12794322 | 0.90 | ALOX5 (0.50) | DGKAALOX5EPHX2PRSS1PRSS2 | |
| SCHEMBL13743189 | 0.90 | ALOX5 (0.50) | DGKAALOX5EPHX2PRSS1PRSS2 | |
| SCHEMBL13743296 | 0.90 | DNM1 (0.59) | DGKAALOX5EPHX2PRSS1PRSS2 | |
| SCHEMBL4813968 | 0.85 | ALOX5 (0.57) | DGKAALOX5EPHX2NAAAPRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9163032-B2 | Esters of DCPLA and methods of treatment using the same | Blanchette Rockefeller Neurosciences Insitute (US) | 2015-10-20 | — | — | US | disclosed |
| US-9163032-B2 | Esters of DCPLA and methods of treatment using the same | Blanchette Rockefeller Neurosciences Insitute (US) | 2015-10-20 | — | — | US | disclosed |
| US-20140323456-A1 | ESTERS OF DCPLA AND METHODS OF TREATMENT USING THE SAME | COGNITIVE RESEARCH ENTERPRISES, INC. | 2014-10-30 | — | — | US | disclosed |
| US-20140323456-A1 | ESTERS OF DCPLA AND METHODS OF TREATMENT USING THE SAME | COGNITIVE RESEARCH ENTERPRISES, INC. | 2014-10-30 | — | — | US | disclosed |
| US-20140315990-A1 | PKC ACTIVATORS AND COMBINATIONS THEREOF | COGNITIVE RESEARCH ENTERPRISES, INC. | 2014-10-23 | — | — | US | disclosed |
| US-20140315990-A1 | PKC ACTIVATORS AND COMBINATIONS THEREOF | COGNITIVE RESEARCH ENTERPRISES, INC. | 2014-10-23 | — | — | US | disclosed |
| WO-2013071282-A1 | PKC ACTIVATORS AND COMBINATIONS THEREOF | BLANCHETTE ROCKEFELLER NEUROSCIENCES INSTITUTE (US) | 2013-05-16 | — | — | WO | disclosed |
| WO-2013071281-A1 | ESTERS OF DCPLA AND METHODS OF TREATMENT USING THE SAME | BLANCHETTE ROCKEFELLER NEUROSCIENCES INSTITUTE (US) | 2013-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323456-A1 | ESTERS OF DCPLA AND METHODS OF TREATMENT USING THE SAME | LIPA, PCCA, PNLIP | DGKA 76/4885ALOX5 130/4885EPHX2 721/4885 |
| US-20140315990-A1 | PKC ACTIVATORS AND COMBINATIONS THEREOF | PRKCH, PRKCB, PRKCA | DGKA 38/4885ALOX5 3192/4885EPHX2 3007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.